Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 7;2(11):1059–1070. doi: 10.1158/2326-6066.CIR-14-0051

Figure 2. Lentivirally-modified GD2 CAR T-cells control disseminated neuroblastoma long-term and prolong animal survival.

Figure 2

Mice with disseminated neuroblastoma were given a single dose of 1×107 CAR T-cells (day 14, black arrow; CD19 cells 56% CAR+, GD2 cells 10.9% CAR+). (A) One dose of GD2 CAR T-cells mediated sustained disease control long-term. (B) Overall survival of animals treated with either CD19 or GD2 CAR T-cells. (C) Disease-related mortality of animals treated with either CD19 or GD2 CAR T-cells. 5/8 animals treated with GD2 CAR T-cells died in disease remission of xenogeneic graft-versus-host disease and 3/8 died with controlled minimal disease burdens of GVHD.